Vol. 6 No. 5 (2026): May
Reimbursement Reviews

Daratumumab (Darzalex SC)

decorative image of the issue cover

Published May 8, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses daratumumab (Darzalex SC), 1800 mg/15 mL (120 mg/mL) single-dose vial solution for subcutaneous injection.
  • Indication: Daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are not candidates for autologous stem cell transplant.